Abbott Laboratories
Market Cap
US$196.6b
Last Updated
2021/01/25 23:42 UTC
Data Sources
Company Financials +
Executive Summary
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Acceptable track record with mediocre balance sheet.
Similar Companies
Share Price & News
How has Abbott Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ABT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: ABT's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
3.1%
ABT
1.0%
US Medical Equipment
2.6%
US Market
1 Year Return
28.1%
ABT
22.0%
US Medical Equipment
26.0%
US Market
Return vs Industry: ABT exceeded the US Medical Equipment industry which returned 22% over the past year.
Return vs Market: ABT exceeded the US Market which returned 26% over the past year.
Shareholder returns
| ABT | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.1% | 1.0% | 2.6% |
| 30 Day | 5.9% | 4.1% | 5.1% |
| 90 Day | 5.7% | 8.9% | 17.1% |
| 1 Year | 30.0%28.1% | 23.1%22.0% | 28.9%26.0% |
| 3 Year | 90.4%81.2% | 66.2%62.0% | 46.3%36.6% |
| 5 Year | 228.4%198.4% | 166.0%146.3% | 126.9%101.6% |
Long-Term Price Volatility Vs. Market
How volatile is Abbott Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Could Abbott Laboratories (NYSE:ABT) Have The Makings Of Another Dividend Aristocrat?2 weeks ago | Simply Wall St
Why You Might Be Interested In Abbott Laboratories (NYSE:ABT) For Its Upcoming Dividend3 weeks ago | Simply Wall St
Abbott Laboratories (NYSE:ABT) Has A Pretty Healthy Balance SheetValuation
Is Abbott Laboratories undervalued compared to its fair value and its price relative to the market?
12.7%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ABT ($114.72) is trading below our estimate of fair value ($131.42)
Significantly Below Fair Value: ABT is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: ABT is poor value based on its PE Ratio (60.7x) compared to the US Medical Equipment industry average (55.7x).
PE vs Market: ABT is poor value based on its PE Ratio (60.7x) compared to the US market (21.3x).
Price to Earnings Growth Ratio
PEG Ratio: ABT is poor value based on its PEG Ratio (4.9x)
Price to Book Ratio
PB vs Industry: ABT is overvalued based on its PB Ratio (6.5x) compared to the US Medical Equipment industry average (5.6x).
Next Steps
Future Growth
How is Abbott Laboratories forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
12.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABT's forecast earnings growth (12.3% per year) is above the savings rate (2%).
Earnings vs Market: ABT's earnings (12.3% per year) are forecast to grow slower than the US market (21.5% per year).
High Growth Earnings: ABT's earnings are forecast to grow, but not significantly.
Revenue vs Market: ABT's revenue (6.7% per year) is forecast to grow slower than the US market (10.6% per year).
High Growth Revenue: ABT's revenue (6.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABT's Return on Equity is forecast to be low in 3 years time (16.1%).
Next Steps
Past Performance
How has Abbott Laboratories performed over the past 5 years?
16.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABT has high quality earnings.
Growing Profit Margin: ABT's current net profit margins (10.4%) are lower than last year (10.4%).
Past Earnings Growth Analysis
Earnings Trend: ABT's earnings have grown by 16.8% per year over the past 5 years.
Accelerating Growth: ABT's earnings growth over the past year (2.1%) is below its 5-year average (16.8% per year).
Earnings vs Industry: ABT earnings growth over the past year (2.1%) exceeded the Medical Equipment industry -0.3%.
Return on Equity
High ROE: ABT's Return on Equity (10.6%) is considered low.
Next Steps
Financial Health
How is Abbott Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: ABT's short term assets ($17.4B) exceed its short term liabilities ($10.3B).
Long Term Liabilities: ABT's short term assets ($17.4B) do not cover its long term liabilities ($27.2B).
Debt to Equity History and Analysis
Debt Level: ABT's debt to equity ratio (55.7%) is considered high.
Reducing Debt: ABT's debt to equity ratio has increased from 39.4% to 55.7% over the past 5 years.
Debt Coverage: ABT's debt is well covered by operating cash flow (37%).
Interest Coverage: ABT's interest payments on its debt are well covered by EBIT (9x coverage).
Balance Sheet
Next Steps
Dividend
What is Abbott Laboratories's current dividend yield, its reliability and sustainability?
1.26%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ABT's dividend (1.26%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.38%).
High Dividend: ABT's dividend (1.26%) is low compared to the top 25% of dividend payers in the US market (3.85%).
Stability and Growth of Payments
Stable Dividend: ABT's dividend payments have been volatile in the past 10 years.
Growing Dividend: ABT's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (76.2%), ABT's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ABT's dividends in 3 years are forecast to be well covered by earnings (32.3% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Robert Ford (46 yo)
0.83
Tenure
US$11,897,886
Compensation
Mr. Robert B. Ford has been the Chief Executive Officer and Director of Abbott Laboratories since March 31, 2020. He has been President and Chief Operating Officer at Abbott Laboratories since October 15, ...
CEO Compensation Analysis
Compensation vs Market: Robert's total compensation ($USD11.90M) is about average for companies of similar size in the US market ($USD10.56M).
Compensation vs Earnings: Robert's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 22yrs | US$27.80m | 0.18% $ 360.3m | |
| CEO, President | 0.83yr | US$11.90m | 0.014% $ 28.1m | |
| Executive Vice President of Nutritional Products | 6.33yrs | US$6.77m | 0.0060% $ 11.8m | |
| Executive Vice President of Medical Devices | 2yrs | US$7.48m | 0.0027% $ 5.2m | |
| Executive VP of Finance & CFO | 0.83yr | no data | 0.012% $ 23.1m | |
| Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 8yrs | US$7.32m | 0.0089% $ 17.4m | |
| VP and Chief Ethics & Compliance Officer | no data | no data | no data | |
| Vice President of Public Affairs & Corporate Marketing | no data | no data | no data | |
| Senior VP and Chief Marketing & External Affairs Officer | 6.08yrs | no data | no data | |
| Executive Vice President of Human Resources | 1.42yrs | no data | 0.0044% $ 8.7m | |
| Senior Vice President of Core Laboratory Diagnostics - Commercial Operations | 7.33yrs | no data | 0.015% $ 28.9m |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Management: ABT's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 22yrs | US$27.80m | 0.18% $ 360.3m | |
| CEO, President | 0.83yr | US$11.90m | 0.014% $ 28.1m | |
| Independent Director | 21yrs | US$326.91k | 0% $ 0 | |
| Independent Director | 11yrs | US$325.91k | 0.00014% $ 275.2k | |
| Lead Independent Director | no data | US$330.91k | 0.0027% $ 5.2m | |
| Independent Director | 3.92yrs | US$300.91k | 0.41% $ 804.2m | |
| Independent Director | 14yrs | US$331.91k | 0.00043% $ 845.2k | |
| Independent Director | 4yrs | US$300.91k | 0.00020% $ 393.1k | |
| Independent Director | 11yrs | US$315.91k | 0.00077% $ 1.5m | |
| Independent Director | 9.08yrs | US$306.91k | no data | |
| Independent Director | 12.25yrs | US$390.23k | no data | |
| Independent Director | 9.08yrs | US$336.27k | 0.00015% $ 294.8k |
11.0yrs
Average Tenure
63.5yo
Average Age
Experienced Board: ABT's board of directors are seasoned and experienced ( 11 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Abbott Laboratories's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Abbott Laboratories
- Ticker: ABT
- Exchange: NYSE
- Founded: 1888
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$196.561b
- Shares outstanding: 1.71b
- Website: https://www.abbott.com
Number of Employees
Location
- Abbott Laboratories
- 100 Abbott Park Road
- Department 377 Building AP6A-1, Abbott park
- North Chicago
- Illinois
- 60064
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ABT | NYSE (New York Stock Exchange) | Yes | Common Shares | US | USD | Jan 1968 |
| 0Q15 | LSE (London Stock Exchange) | Yes | Common Shares | GB | USD | Jan 1968 |
| ABT | SWX (SIX Swiss Exchange) | Yes | Common Shares | CH | CHF | Jan 1968 |
| ABT * | BMV (Bolsa Mexicana de Valores) | Yes | Common Shares | MX | MXN | Jan 1968 |
| ABL | XTRA (XETRA Trading Platform) | Yes | Common Shares | DE | EUR | Jan 1968 |
| ABL | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jan 1968 |
| ABT | SNSE (Santiago Stock Exchange) | Yes | Common Shares | CL | USD | Jan 1968 |
| ABT | BASE (Buenos Aires Stock Exchange) | CEDEAR EACH 4 REP 1 | AR | ARS | Sep 2000 | |
| ABTT34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 4 REP 1 COM | BR | BRL | Aug 2012 |
Biography
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreat...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/25 23:42 |
| End of Day Share Price | 2021/01/25 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.